More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.
Advertisement
Advertisement
Trending on CancerNetwork
1
ASCENT-03: Sacituzumab Govitecan Versus Chemotherapy in First-Line Metastatic TNBC
2
Contextualizing MRD Negativity and PFS Across Treatment Regimens in Relapsed/Refractory Multiple Myeloma
3
EXCALIBER-RRMM Trial Results: MRD Negativity and Progression-Free Survival in Relapsed/Refractory Multiple Myeloma
4
How Should Belzutifan Plus Lenvatinib Fit Into Advanced RCC Sequencing?
5